Biocon Limited has announced a board meeting scheduled for May 07, 2026, to approve its financial results for the fourth quarter and full financial year 2025-26. The meeting will address key financial matters including dividend considerations and routine corporate affairs.

Board Meeting Details

The Board of Directors meeting is scheduled to take place on Thursday, May 07, 2026. The primary agenda includes approval and recording of audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026.

Trading Window Restrictions

In compliance with insider trading regulations, Biocon has implemented a trading window closure for company securities. The restrictions are in effect from Wednesday, April 01, 2026 to Saturday, May 09, 2026, both days inclusive.

Earnings Conference Call

Biocon will conduct an earnings conference call for analysts and investors following the board meeting. The call is scheduled for Friday, May 08, 2026 at 09:00 hrs IST and will be conducted via Zoom platform.

Recording and Documentation

The company will provide comprehensive documentation of the earnings call:

• Audio recording will be available before the next trading day or within 24 hours from call conclusion
• Video recording will be accessible within 48 hours of call completion
• Conference call transcript will be published within 5 working days
• All recordings and transcripts will be available on the company website under Investors section

Participants are advised to join the conference call 10 minutes before the scheduled start time. The investor relations contact for further information is Prashant Nair, who can be reached at +91 6775 1714 or prashant.nair@biocon.com .

Biocon Limited has achieved a significant regulatory milestone with Health Canada's approval of two denosumab biosimilars on April 3, 2026, marking another expansion of the company's global biosimilar portfolio. The company announced this development through an official press release filed under Regulation 30 on April 21, 2026, with both BSE Limited and National Stock Exchange of India Limited.

Health Canada Approval Details

Health Canada granted Notice of Compliance (NOC) for both biosimilars in their most common presentations. The regulatory approval encompasses specific formulations designed for optimal patient care:

Both products are approved for subcutaneous administration and target the RANKL pathway, which is essential for bone resorption processes. The approval is based on comprehensive analytical, nonclinical, and clinical data demonstrating that both biosimilars are highly similar to their reference products with no clinically meaningful differences in quality, safety, or efficacy.

Treatment Applications and Patient Impact

Bosaya™ addresses multiple osteoporosis-related conditions across diverse patient populations. The biosimilar is approved for treating postmenopausal women with osteoporosis at high risk for fracture and increasing bone mass in men with osteoporosis at high risk for fracture. Additionally, it covers specialized applications including treatment for men with nonmetastatic prostate cancer receiving androgen deprivation therapy and women with nonmetastatic breast cancer receiving adjuvant aromatase inhibitor therapy. The product also treats patients at high risk for fracture due to sustained systemic glucocorticoid therapy.

Vevzuo™ focuses on cancer-related bone complications and specialized bone conditions. The biosimilar is approved for reducing skeletal-related events in patients with multiple myeloma and bone metastases from breast cancer, prostate cancer, non-small cell lung cancer, and other solid tumours. It also treats adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection would result in severe morbidity, plus treatment of hypercalcemia of malignancy refractory to intravenous bisphosphonate.

Clinical Significance and Market Potential

The approvals potentially benefit more than 2 million adults with osteoporosis and hundreds of patients annually with bone metastasis, a common complication of advanced cancer. Denosumab products play a key role in bone health by targeting and binding to Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL), which is essential for osteoclast formation, function, and survival.

Management Commentary and Strategic Impact

Shreehas Tambe, CEO & Managing Director of Biocon Ltd., emphasized the milestone's significance for the company's global expansion strategy. He stated that Health Canada's approval of BOSAYA and VEVZUO marks another important milestone as Biocon continues expanding access to high-quality biosimilars in key global markets. The approval reflects the company's strong scientific and regulatory capabilities and reinforces its commitment to patients living with osteoporosis and cancer-related bone conditions, while further strengthening the portfolio of affordable biologic therapies across immunology and oncology.

Safety Considerations and Clinical Monitoring

Both biosimilars require careful clinical monitoring and patient management. Key safety considerations for Bosaya™ include hypocalcemia correction through adequate calcium and vitamin D intake prior to therapy initiation, monitoring for hypersensitivity reactions including anaphylaxis, and awareness of potential serious infections. Vevzuo™ carries similar safety profiles with additional considerations for cancer patients, including calcium level assessment prior to initial dosing and careful management in patients with renal impairment. Both products require monitoring for osteonecrosis of the jaw and atypical femoral fractures.